SCYNEXIS (SCYX) Competitors $0.81 0.00 (-0.30%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$0.82 +0.01 (+0.74%) As of 10/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. HURA, TVGN, OVID, ATOS, BMEA, ZYBT, KLRS, IKT, VIRI, and TILShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include TuHURA Biosciences (HURA), Tevogen Bio (TVGN), Ovid Therapeutics (OVID), Atossa Genetics (ATOS), Biomea Fusion (BMEA), Zhengye Biotechnology (ZYBT), Kalaris Therapeutics (KLRS), Inhibikase Therapeutics (IKT), Virios Therapeutics (VIRI), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Its Competitors TuHURA Biosciences Tevogen Bio Ovid Therapeutics Atossa Genetics Biomea Fusion Zhengye Biotechnology Kalaris Therapeutics Inhibikase Therapeutics Virios Therapeutics Instil Bio TuHURA Biosciences (NASDAQ:HURA) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation. Do analysts recommend HURA or SCYX? TuHURA Biosciences presently has a consensus target price of $12.67, suggesting a potential upside of 394.79%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe TuHURA Biosciences is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is HURA or SCYX more profitable? TuHURA Biosciences has a net margin of 0.00% compared to SCYNEXIS's net margin of -599.05%. SCYNEXIS's return on equity of -43.04% beat TuHURA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A -248.79% -150.83% SCYNEXIS -599.05%-43.04%-28.21% Does the media prefer HURA or SCYX? In the previous week, SCYNEXIS had 5 more articles in the media than TuHURA Biosciences. MarketBeat recorded 6 mentions for SCYNEXIS and 1 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.83 beat SCYNEXIS's score of 0.78 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Overall Sentiment TuHURA Biosciences Positive SCYNEXIS Positive Which has preferable earnings and valuation, HURA or SCYX? SCYNEXIS has higher revenue and earnings than TuHURA Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$21.68MN/AN/ASCYNEXIS$3.75M9.05-$21.29M-$0.40-2.03 Do institutionals and insiders have more ownership in HURA or SCYX? 0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 4.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, HURA or SCYX? TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. SummarySCYNEXIS beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks. Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.06M$2.96B$6.11B$10.45BDividend YieldN/A57.77%5.73%4.77%P/E Ratio-2.0222.7985.3627.36Price / Sales9.05783.65596.99137.58Price / CashN/A172.6337.4661.86Price / Book0.565.5112.286.81Net Income-$21.29M$33.06M$3.32B$276.80M7 Day Performance2.32%0.23%0.59%0.42%1 Month Performance-23.58%14.73%10.54%7.86%1 Year Performance-47.40%-1.42%70.62%41.24% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS0.654 of 5 stars$0.81-0.3%N/A-46.4%$34.06M$3.75M-2.0260News CoverageAnalyst ForecastGap UpHigh Trading VolumeHURATuHURA Biosciences1.671 of 5 stars$2.49-4.2%$12.67+408.7%N/A$132.87MN/A0.00N/ATVGNTevogen Bio2.8464 of 5 stars$0.65-3.7%$10.00+1,441.3%-44.9%$132.56MN/A-3.413News CoverageOVIDOvid Therapeutics4.5389 of 5 stars$1.79-2.7%$3.10+73.2%+43.5%$130.84M$6.65M-3.3860ATOSAtossa Genetics2.6126 of 5 stars$1.00-1.0%$6.25+525.0%-26.6%$130.46MN/A-4.358News CoverageAnalyst DowngradeGap UpBMEABiomea Fusion3.3413 of 5 stars$2.67+24.2%$9.50+255.8%-85.0%$127.94MN/A-0.8850High Trading VolumeZYBTZhengye BiotechnologyN/A$2.88+7.5%N/AN/A$126.41M$25.53M0.00278News CoverageAnalyst ForecastKLRSKalaris Therapeutics1.3786 of 5 stars$8.03+20.9%$3.00-62.6%N/A$124.18MN/A0.00110High Trading VolumeIKTInhibikase Therapeutics0.053 of 5 stars$1.62-2.4%N/AN/A$123.70M$260K0.006Gap DownVIRIVirios TherapeuticsN/A$6.41-0.2%$5.00-22.0%+70.5%$123.44MN/A-23.745News CoverageTILInstil Bio3.3063 of 5 stars$18.43+1.8%$88.50+380.2%-47.6%$122.19MN/A-1.43410Positive NewsAnalyst Forecast Related Companies and Tools Related Companies HURA Alternatives TVGN Alternatives OVID Alternatives ATOS Alternatives BMEA Alternatives ZYBT Alternatives KLRS Alternatives IKT Alternatives VIRI Alternatives TIL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
